# OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)

> **NCT01197261** · PHASE2 · COMPLETED · sponsor: **Mundipharma Research GmbH & Co KG** · enrollment: 120 (actual)

## Conditions studied

- Interstitial Cystitis
- Painful Bladder Syndrome
- Pain

## Interventions

- **DRUG:** Oxycodone naloxone prolonged release tablets
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT01197261
- **Lead sponsor:** Mundipharma Research GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197261, "OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01197261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*